-
公开(公告)号：US20240316149A1
公开(公告)日：2024-09-26
申请号：US18574173
申请日：2022-06-24
CPC分类号： A61K38/1722 , A01N1/0226 , A61K47/54 , A61K47/60 , A61K47/61 , A61K47/64 , A61K47/6445
摘要： Disclosed are hemoglobin-based oxygen carriers (HBOCs) that comprise a polymer-functionalized polymerized hemoglobin, such as a polyalkylene oxide (PAO)-functionalized polymerized hemoglobin, as well as compositions comprising these HBOCs (e.g., dissolved or dispersed in an aqueous carrier) and methods of making and using thereof.
-
公开(公告)号：US20230190947A1
公开(公告)日：2023-06-22
申请号：US16310197
申请日：2017-06-21
发明人： Steven Brookes , J. Gordon Adamson , David Bell
CPC分类号： A61K47/6445 , A61P35/04 , A61P35/00 , A61P1/00
摘要： The use of hemoglobin as a targeting carrier for drugs is disclosed. Such hemoglobin-drug complexes have utility in the treatment of cancer, in particular cancers of the liver and colon. Said drug is preferably a nucleoside analog, in particular floxuridine and is covalently attached to the hemoglobin in a molar drug ratio of between 1 and 20.
-
公开(公告)号：US20170266285A1
公开(公告)日：2017-09-21
申请号：US15469978
申请日：2017-03-27
CPC分类号： A61K45/06 , A61K38/42 , A61K47/6445 , A61K49/0043 , A61K49/0056 , A61K51/088
摘要： The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.
-
公开(公告)号：US20160158368A1
公开(公告)日：2016-06-09
申请号：US14928528
申请日：2015-10-30
发明人： Irina Ayres , Murray J. Cutler , Kathryn Matthews , Steven Brookes , J. Gordon Adamson , David N. Bell
IPC分类号： A61K47/48 , A61K31/7064 , A61K31/7076
CPC分类号： A61K31/7064 , A61K31/7076 , A61K47/6445
摘要： The present application provides methods of treating CD163+ histiocytosis comprising administering an effective amount of a CD163 ligand-drug conjugate to an animal or cell in need thereof.
摘要翻译： 本申请提供了治疗CD163 +组织细胞增多症的方法，包括向有需要的动物或细胞施用有效量的CD163配体 - 药物缀合物。
-
公开(公告)号：US08609814B2
公开(公告)日：2013-12-17
申请号：US12452075
申请日：2008-06-26
IPC分类号： A61K35/14
CPC分类号： C07K14/805 , A61K38/00 , A61K47/60 , A61K47/62 , A61K47/6445
摘要： The present invention relates to a modified porphyrin-based oxygen-carrying protein, such as haemoglobin, which has been found, in its unmodified state to have a low affinity site of electron transfer and a high affinity electron transfer between a reductant and ferryl haem iron via one or more protein amino acids. The invention provides such proteins that comprise a modification to enhance this pathway.
摘要翻译： 本发明涉及一种修饰的卟啉基携氧蛋白，如血红蛋白，已发现其未修饰状态具有低的电子转移亲和力位点和还原剂与铁氧体铁之间的高亲和力电子转移 通过一种或多种蛋白质氨基酸。 本发明提供了包含增强该途径的修饰的蛋白质。
-
公开(公告)号：US07795219B2
公开(公告)日：2010-09-14
申请号：US12006849
申请日：2008-01-07
IPC分类号： A61K38/00
CPC分类号： A61K38/1709 , A61K31/21 , A61K33/00 , A61K35/18 , A61K38/00 , A61K38/42 , A61K45/06 , A61K47/08 , A61K47/16 , A61K47/6445 , A61K2300/00
摘要： The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects. In some embodiments, the presently disclosed methods involve administering to subjects in need thereof a first composition selected from the group consisting of a nitrosylated hemoglobin and an agent that induces nitrosylation of endogenous hemoglobin in the subject and a second composition comprising a hyperoxic gas. In some embodiments, the presently disclosed methods also include treating a tumor with radiation therapy, chemotherapy, photodynamic therapy, immunotherapy, or combinations thereof. Also provided are inhalable gases that can be employed in the presently disclosed methods.
-
公开(公告)号：US07329543B2
公开(公告)日：2008-02-12
申请号：US11179349
申请日：2005-07-12
IPC分类号： C12N5/06
CPC分类号： A61K31/00 , A61K31/04 , A61K31/095 , A61K31/195 , A61K33/00 , A61K38/1816 , A61K47/54 , A61K47/6445 , A61K47/6901 , C07K14/00 , G01N21/631 , G01N21/76 , G01N33/721
摘要： Red blood cells can be loaded with low molecular weight nitrosylating agents, such as S-nitrosothiols, to act as a delivery system for NO+ groups to tissues. Loaded red blood cells can be used in methods of therapy for conditions which are characterized by abnormal O2 metabolism of tissues, oxygen-related toxicity, abnormal vascular tone, abnormal red blood cell adhesion, or abnormal O2 delivery by red blood cells. Such treatment of red blood cells can be extended to in vivo therapies, with the object to achieve an increase in the ratio of red blood cell S-nitrosothiol to hemoglobin.
摘要翻译： 红细胞可以装载低分子量亚硝酰化剂，如S-亚硝基硫醇，作为组织的NO + +组的递送系统。 加载的红细胞可以用于治疗方法，其特征在于组织的异常O 2代谢，氧相关毒性，异常血管紧张度，异常红细胞粘附或异常的O < 通过红细胞递送SUB> 2 。 红细胞的这种治疗可以延伸到体内治疗，其目的是实现红细胞S-亚硝基硫醇与血红蛋白的比例的增加。
-
公开(公告)号：US20070275878A1
公开(公告)日：2007-11-29
申请号：US11784780
申请日：2007-04-09
申请人： Jonathan Stamler , Andrew Gow
发明人： Jonathan Stamler , Andrew Gow
IPC分类号： A61K38/16
CPC分类号： A61K31/00 , A61K31/04 , A61K31/095 , A61K31/195 , A61K35/18 , A61K38/00 , A61K38/44 , A61K47/6445 , A61K47/6901 , C07K14/00 , C07K14/805 , G01N21/631 , G01N21/76 , G01N33/721 , Y10T436/105831
摘要： Nitrosylhemoglobin can be produced by introducing gaseous NO into an aqueous solution of hemoglobin. It has been demonstrated that nitrosylhemoglobin in aqueous solution can be converted to SNO-hemoglobin upon introduction of oxygen to the solution, as is postulated to occur in the lungs. Nitrosylhemoglobin can be used in methods to produce the physiological effects of NO, for example, to reduce vasoconstriction and to inhibit platelet aggregation.
-
公开(公告)号：US07235639B2
公开(公告)日：2007-06-26
申请号：US10420966
申请日：2003-04-23
申请人： Ezio Panzeri
发明人： Ezio Panzeri
CPC分类号： C07K14/805 , A61K38/42 , A61K47/6445 , A61K2300/00
摘要： The invention provides a conjugate of hemoglobin and a nucleic acid cross-linking agent.
摘要翻译： 本发明提供血红蛋白和核酸交联剂的缀合物。
-
公开(公告)号：US06916471B2
公开(公告)日：2005-07-12
申请号：US10045603
申请日：2001-10-23
IPC分类号： A61K31/00 , A61K31/04 , A61K31/095 , A61K31/195 , A61K35/18 , A61K38/00 , A61K38/42 , A61K47/48 , C07K14/00 , G01N21/63 , G01N21/76 , G01N33/72 , C12N5/06
CPC分类号： A61K31/00 , A61K31/04 , A61K31/095 , A61K31/195 , A61K33/00 , A61K38/1816 , A61K47/54 , A61K47/6445 , A61K47/6901 , C07K14/00 , G01N21/631 , G01N21/76 , G01N33/721
摘要： Red blood cells can be loaded with low molecular weight nitrosylating agents, such as S-nitrosothiols, to act as a delivery system for NO+ groups to tissues. Loaded red blood cells can be used in methods of therapy for conditions which are characterized by abnormal O2 metabolism of tissues, oxygen-related toxicity, abnormal vascular tone, abnormal red blood cell adhesion, or abnormal O2 delivery by red blood cells. Such treatment of red blood cells can be extended to in vivo therapies, with the object to achieve an increase in the ratio of red blood cell S-nitrosothiol to hemoglobin.
摘要翻译： 红细胞可以装载低分子量亚硝酰化剂，如S-亚硝基硫醇，作为组织的NO + +组的递送系统。 加载的红细胞可以用于治疗方法，其特征在于组织的异常O 2代谢，氧相关毒性，异常血管紧张度，异常红细胞粘附或异常的O < 通过红细胞递送SUB> 2 。 红细胞的这种治疗可以延伸到体内治疗，其目的是实现红细胞S-亚硝基硫醇与血红蛋白的比例的增加。
-
-
-
-
-
-
-
-
-
搜索结果
78 条记录 (耗时 0.031 秒)
